SOMAÍ Pharmaceuticals

Home
Australia
Brisbane, QLD
SOMAÍ Pharmaceuticals

Somai is fast becoming one of the most recognized and well-developed pharmaceutical brands in the EU.

A leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio Somai Pharmaceuticals LTD is a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoid-containing pharmaceuticals throughout the European Union and globally. Somai emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Somai's product development knowledge was honed in the competitive American market, and is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's. Somai has brought together an all-star team of scientists and KOL's from around the world with various clinical experiences to guide Somai's product development and acceptance globally. Somai stresses education and continual R&D, which started from the USA as transformative developments, to help EU doctors and patients properly diagnose and treat the individual indications by providing variable dosage choices. Somai’s primary goal is producing the most advanced products with the most innovative delivery methods to create maximum bioavailability and healing for patients. As a global biotech player concentrating on cannabinoids, Somai has a unique pipeline of current and future products that will be on the market starting in late 2022. They already boast one of the largest IP (Intellectual Property) vaults of APIs that weren’t accessible to Europe until recently. Somai’s near term products conform to the highest standards of herbal medicine (ACM) and specialized cannabinoid API’s for R&D, but also keeps a steady eye on the horizon of future clinical trials for their proprietary pipeline, setting it up to be well positioned for the next decade.

19/02/2026

🔵 Celebrating 7 Years of SOMAÍ 🎉

Seven years ago, Michael Sassano and George Bellow founded SOMAÍ with a vision: to build a globally leading pharmaceutical company that would shape the future of EU-GMP cannabinoid-based medicine.

Since then, SOMAÍ has:

🔷 Built a state-of-the-art EU-GMP manufacturing facility
🔷 Achieved EU-GMP licensing within just one year
🔷 Grown into a vertically integrated Multi-Country Operator (MCO) with a presence across Europe, the UK, APAC, and beyond
🔷 Established NovaSoma, our advanced indoor cultivation facility in Lisbon, operating under strict pharmaceutical and environmental controls
🔷 Developed one of the most comprehensive EU-GMP-certified extract portfolios
🔷 Launched multiple product lines, including Essentials, Origins, Senses, and Inhalation Oils
🔷 Advanced scientific research and strategic global partnerships

From a bold idea to a global pharmaceutical platform, SOMAÍ continues to raise the standard for cannabinoid-based medicines — combining cultivation excellence, EU-GMP precision, and international distribution expertise.

Thank you to our team, partners, and patients for being part of this journey.

Here’s to the next chapter. 🌐

17/02/2026

SOMAÍ today announced a strategic partnership with KISEKI PLANT FACTORY to support the global distribution of KISEKI’s medicinal cannabis flower across SOMAÍ’s international medical markets.

Through this collaboration, KISEKI’s medicinal cannabis products will become available for the first time in the UK, leveraging SOMAÍ’s established regulatory infrastructure and pharmaceutical distribution network. This milestone represents one of the first introductions of a Japanese-origin cannabis brand into Western prescription markets. The partnership will continue to expand in phases, aligned with applicable market authorization processes and regulatory requirements.

“Japanese quality is the result of precise plant-factory engineering, disciplined cultivation processes, and carefully selected genetics,” said Kohei Yamada, Founder and CEO of KISEKI PLANT FACTORY (THAILAND) Co., Ltd. “We are proud to collaborate with SOMAÍ to bring our medicinal cannabis to patients worldwide through a partner that understands regulated medical markets.”

“This collaboration reflects SOMAÍ’s role in working to distribute various craft indoor brands through its global distribution platform,” said Sassano, Founder and Interim CEO of SOMAÍ. “SOMAÍ’s ability to navigate EU-GMP regulatory frameworks to commercialization of unique international brands demonstrates careful thought to reach many demographics in the medical community through diversified cultural offerings that meet the high expectations of regulators, prescribers, and patients worldwide.”

Read the full news: https://www.einpresswire.com/article/892881634/soma-partners-with-japan-s-kiseki-to-introduce-japanese-quality-medicinal-cannabis-to-global-medical-markets

10/02/2026

We’re pleased to introduce Inês Lima, a new Regulatory Affairs Manager & Technical Director of Wholesale Distribution at SOMAÍ.

With a background in Pharmaceutical Sciences, Inês has been dedicated to medical cannabis since the beginning of her career. Trained in GMP, GDP, and ISO 9001, she combines academic expertise with hands-on experience in pharmaceutical quality systems and has played an active role in the sector’s regulatory development in Portugal.

In her role at SOMAÍ, Inês leads regulatory engagement, audits, and quality systems across the supply chain — ensuring alignment with the highest pharmaceutical standards across national and international markets. Her work plays a central role in supporting compliant growth, product differentiation, and sustainable patient access.

“SOMAÍ stands out not only for its rigor and quality standards, but also for continuous innovation and increasingly personalized patient access. It is an honour to be part of an organisation that raises the bar for quality and science in medical cannabis,” Inês shared.

With a strong focus on patients, science, and continuous improvement, Inês sees SOMAÍ further consolidating its position as a global reference in cannabinoid-based medicines — advancing innovation while maintaining uncompromising regulatory excellence.

Welcome to the team, Inês.

06/02/2026

Designed for reliable onset when timing matters.

06/02/2026

Designed for reliable onset when timing matters.

03/02/2026

🔵 We’re Hiring in Australia 🇦🇺

SOMAÍ is expanding its global footprint and we’re looking for an experienced Brand Manager to lead and grow our presence in the Australian medical cannabis market, balancing growth objectives with strict regulatory requirements.

🔹 Lead go-to-market strategy and product launches
🔹 Develop compliant marketing and educational materials for HCPs
🔹 Manage digital campaigns, CRM activity, and content calendars
🔹 Work closely with global teams while owning local ex*****on

100% remote | High-impact role | Global support

Apply here: https://www.seek.com.au/job/89979138

29/01/2026

We’re heading to Brisbane!

SOMAÍ is a Bronze Sponsor of UIC 2026 and we’ll be on the expo floor all conference long.

Be sure to catch CEO Michael Sassano’s talk on our latest scientific publications, and then swing by our booth to learn from Sam, Renee & Judi.

Catch you February 26-28.

20/01/2026

SOMAÍ today announced that it has received official approval from INFARMED, Portugal’s National Authority of Medicines and Health Products, to commercialize three of its medical cannabis products in Portugal, and also received independently a Portuguese GDP distribution license that enables direct commercialization and supply.

This market authorization ACM and distribution license approval marks a significant milestone for SOMAÍ, enabling the company to supply the Portuguese medical cannabis market with EU-GMP-certified cannabinoid medicines manufactured in Portugal, in full compliance with national and European regulatory standards.

“This approval represents an important moment for SOMAÍ and for Portugal’s medical cannabis ecosystem,” said Sassano, Founder and Interim CEO of SOMAÍ. “Having an official medical market-authorized product in Portugal and the EU is another milestone accomplished that will supply Portuguese patients, but the bigger picture is that SOMAÍ has already invested significantly in developing comprehensive regulatory dossiers that can access the hardest medical markets in European and global markets, including Spain, France, Poland, New Zealand, and other strictly medical markets. SOMAÍ's investment in dossiers further reinforces our strategy to reach all cannabis markets and provide access to our extract portfolio to patients in all approved markets.”

Read the full news here: https://www.einpresswire.com/article/884621464/soma-secures-product-and-distribution-authorization-in-portugal

13/01/2026

SOMAÍ and Universidade Lusófona - Centro Universitário Lisboa have published their 4th peer-reviewed study titled “Genotype and chemotype insights of high-THC medicinal Cannabis sativa L.: the role of SSR markers in the identification of cultivars” in the Journal of Cannabis Research.

The paper presents a scientifically validated framework that supports genetic and chemical consistency in high-THC medicinal cannabis oils—reinforcing SOMAÍ’s commitment to evidence-based pharmaceutical manufacturing and regulatory excellence across global medical markets.

“At SOMAÍ, we are making more than an extensive product array; we continue to invest in scientific studies to differentiate our products for doctors and patients around the globe. With a belief that pharmaceutical cannabis demands the same rigor as any other medicinal product, this study demonstrates how genetics, chemistry, and GMP processes work together to guarantee consistency for patients and confidence for prescribers,” said Michael Sassano, Founder and Interim CEO of SOMAÍ. “As more markets adopt higher regulatory expectations, Somai will continue to be first in researching the future of cannabis-based extract medicines.”

“This research provides the scientific framework needed to guarantee batch-to-batch consistency in cannabis medicines. By integrating genotype and chemotype verification, we are able to confirm the reliability and reproducibility expected in any pharmaceutical product,” said Professor Maria do Céu Costa of Universidade Lusófona. “Working with SOMAÍ allowed us to translate this methodology directly into real-world EU-GMP manufacturing, ensuring patients benefit from truly standardized formulations.”

Read the news: https://www.einpresswire.com/article/882572511/soma-and-universidade-lus-fona-publish-peer-reviewed-study-validating-full-spectrum-oil-consistency

05/01/2026

SOMAÍ announces the launch of its Mint Oral Solutions line in Switzerland, marking the next phase of its collaboration with Dascoli Pharma AG.

The Mint Oral Solutions line has been developed to combine pharmaceutical precision with improved patient compliance and treatment adherence. Created using SOMAÍ’s advanced purification process, the formulations feature a refreshing peppermint terpene mix that offers a more pleasant experience for patients requiring long-term treatment. Each product in the line maintains consistent cannabinoid profiles, high bioavailability, and EU-GMP-certified quality, reflecting SOMAÍ’s commitment to innovation and patient-centric design.

“Our ongoing collaboration with Dascoli Pharma AG allows SOMAÍ to continue expanding access to our cannabinoid formulations through a trusted partner that shares our vision of pharmaceutical integrity and medical compliance,” said Michael Sassano, Founder of SOMAÍ. “The introduction of the Mint Oral Solutions line builds on the success of our Essentuals range and reinforces SOMAÍ’s position as a leader in EU-GMP cannabinoid-based medicines.”

Read the full news here: https://somaipharma.eu/news/somai-expands-partnership-with-dascoli-pharma-ag-to-launch-mint-oral-solutions-line-in-switzerland/

30/12/2025

🔹 Ending 2025 with a conversation about what comes next.

On the latest Give and T**e episode, host Paul O’Donoghue is joined by SOMAÍ’s Interim CEO and Founder, Michael Sassano — a leader known for calling global market shifts early — to look back at 2025 and explore what 2026 could bring across the world.

🌀 Market outlooks
🌍 Global trends
🔵 What to watch in 2026

🎧 Tune in: https://giveandtoke.transistor.fm/episodes/what-2025-taught-us-about-global-cannabis-w-michael-sassano-somai

🔹 And stay tuned for what will bring in 2026.

22/12/2025

The second half of this year has flown by. Our SOMAÍ Australia team has been on the move - attending conferences, building new relationships, reconnecting with familiar faces, and visiting clients across the country. We travelled to Thailand for an education tour of cultivation facilities, deepened our industry connections, supported dispensaries and clinics, engaged with prescribers, and listened to the experiences of patients.

It’s been rewarding, and we can't wait for 2026.

Address

Brisbane, QLD

Website

http://www.somaipharma.eu/

Alerts

Be the first to know and let us send you an email when SOMAÍ Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to SOMAÍ Pharmaceuticals:

Want your practice to be the top-listed Clinic in Brisbane?

SOMAÍ Pharmaceuticals

19/02/2026

17/02/2026

10/02/2026

06/02/2026

06/02/2026

03/02/2026

29/01/2026

20/01/2026

13/01/2026

05/01/2026

30/12/2025

22/12/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category